Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: biogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2025 | $118.00 | Buy → Hold | HSBC Securities |
| 4/4/2025 | Buy → Hold | Argus | |
| 2/11/2025 | $160.00 | Mkt Perform | Bernstein |
| 1/2/2025 | $315.00 → $138.00 | Overweight → Neutral | Piper Sandler |
| 12/20/2024 | $230.00 → $164.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/16/2024 | $175.00 | Buy → Hold | Stifel |
| 12/10/2024 | $178.00 | Neutral | BofA Securities |
| 12/9/2024 | $250.00 → $180.00 | Buy → Hold | Jefferies |
| 11/18/2024 | Buy → Hold | Needham | |
| 11/15/2024 | Peer Perform | Wolfe Research |
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
3 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
FWP - BIOGEN INC. (0000875045) (Subject)
S-3ASR - BIOGEN INC. (0000875045) (Filer)
10-Q - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
DEF 14A - BIOGEN INC. (0000875045) (Filer)
DEFA14A - BIOGEN INC. (0000875045) (Filer)
10-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD TOKYO and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. "We are encouraged by the FDA's Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer's disease," said Priya Singhal, M.D., M.P.H., Hea
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and
Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprintNew building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen's presence in Kendall Square, integrating Biogen's research and development and tec
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1Felzartamab, with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen's late-stage immunology portfolio CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult
TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"), Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", ) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) today announced a collaboration for the development and
Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD) in the European Union. In November 2024, a positive opinion was received from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of lecanemab.1 As part of its decision-making process, the European Commi
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00
Argus downgraded Biogen from Buy to Hold
Bernstein initiated coverage of Biogen with a rating of Mkt Perform and set a new price target of $160.00
Piper Sandler downgraded Biogen from Overweight to Neutral and set a new price target of $138.00 from $315.00 previously
BMO Capital Markets downgraded Biogen from Outperform to Market Perform and set a new price target of $164.00 from $230.00 previously
Stifel downgraded Biogen from Buy to Hold and set a new price target of $175.00
BofA Securities resumed coverage of Biogen with a rating of Neutral and set a new price target of $178.00
Jefferies downgraded Biogen from Buy to Hold and set a new price target of $180.00 from $250.00 previously
Needham downgraded Biogen from Buy to Hold
Wolfe Research initiated coverage of Biogen with a rating of Peer Perform
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-31) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 03/12/2024. Application Category: NDA, Application Number: 204063, Application Classification: Labeling
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-16) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-32) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 204063, Application Classification: Labeling
Submission status for BIOGEN INC's drug ADUHELM (SUPPL-11) with active ingredient ADUCANUMAB-AVWA has changed to 'Approval' on 08/30/2023. Application Category: BLA, Application Number: 761178, Application Classification:
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-9) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 211855, Application Classification: Efficacy
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-29) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 204063, Application Classification: Efficacy
Submission status for BIOGEN INC's drug ADUHELM (SUPPL-7) with active ingredient ADUCANUMAB-AVWA has changed to 'Approval' on 02/08/2023. Application Category: BLA, Application Number: 761178, Application Classification:
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and
Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). "We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With the transaction now complete, we will begin working together with our colleagues from HI-Bio on plans to advance felzart
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a
Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints Zuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with prior studies Postpartum depression is one of the most common medical complications during and after pregnancy impacting approximately 1 in 8 women annually in the U.S. Sage Therapeutics to host conference call today at 8:00 am ET Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing depressive symptoms compared to an antidepressant co-initiated with placebo over the 2-week treatment period Zuranolone 50 mg co-initiated with a standard of care antidepressant was generally well-tolerated with most TEAEs reported as mild or moderate and no new safety signals identified Sage Therapeutics to host conference call today at 8:00 a.m. ET Sage Therapeutics, Inc. (NASDAQ:SAGE), and Biogen
Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, 2021 at 8:00am ET Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD) presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 2-5, 2021. Presentat
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ("3M"), to the Company's Board of Directors (the "Board"), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee. "We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter," said Caroline Dorsa, Chair of the Biogen Board of Directors. "Monish's deep financial expertise and diversified management experience at leadin
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. "Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies. I believe Jane will be a strong asset to Biogen as we seek to bring a greater number of innovative medicines to market faster and more effectively," said Mr. Viehbacher. "Together with Dr. Pr
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. "We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable experience in biopharmaceutical strategy and business development with a solid track record of value-creating deals throughout his career," said Mr. Viehbacher. "As we are working to put Biogen on a sus
CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer. "Chuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I'm pleased to welcome him to our leadership team," said Michael McDonnell, Executive Vice President and Chief Financial Officer. "His wealth of experience collaborating with company leaders through periods of strong growth and transition will enhance our continuous efforts to inform invest
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today that Alfred "Al" W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr. Sandrock, 64, led the development of many of the Company's most important and transformational therapies in neurological diseases, including Tysabri® (natalizumab), Tecfidera® (dimethyl fumarate), Spinraza® (nusinersen), Plegridy® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen's Executive Committee since 2015, as Head of Research & Development since October 2019, and as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group. The total committed funding at launch with the upfront payments from the two partnerships and Series A financing is $110 million. Atalanta was founded to address a central limitation for today’s RNAi therapeutics: the difficulty of achieving distribution throughout the brain and spinal cord. Atalanta’s proprietary technology, called branched siRNA